Diabetes and alpha lipoic Acid
- PMID: 22125537
- PMCID: PMC3221300
- DOI: 10.3389/fphar.2011.00069
Diabetes and alpha lipoic Acid
Abstract
Diabetes mellitus is a multi-faceted metabolic disorder where there is increased oxidative stress that contributes to the pathogenesis of this debilitating disease. This has prompted several investigations into the use of antioxidants as a complementary therapeutic approach. Alpha lipoic acid, a naturally occurring dithiol compound which plays an essential role in mitochondrial bioenergetic reactions, has gained considerable attention as an antioxidant for use in managing diabetic complications. Lipoic acid quenches reactive oxygen species, chelates metal ions, and reduces the oxidized forms of other antioxidants such as vitamin C, vitamin E, and glutathione. It also boosts antioxidant defense system through Nrf-2-mediated antioxidant gene expression and by modulation of peroxisome proliferator activated receptors-regulated genes. ALA inhibits nuclear factor kappa B and activates AMPK in skeletal muscles, which in turn have a plethora of metabolic consequences. These diverse actions suggest that lipoic acid acts by multiple mechanisms, many of which have only been uncovered recently. In this review we briefly summarize the known biochemical properties of lipoic acid and then discussed the oxidative mechanisms implicated in diabetic complications and the mechanisms by which lipoic acid may ameliorate these reactions. The findings of some of the clinical trials in which lipoic acid administration has been tested in diabetic patients during the last 10 years are summarized. It appears that the clearest benefit of lipoic acid supplementation is in patients with diabetic neuropathy.
Keywords: alpha lipoic acid; antioxidant; diabetes; nephropathy; neuropathy; oxidative stress.
Figures
Similar articles
-
Alpha-lipoic acid supplementation and diabetes.Nutr Rev. 2008 Nov;66(11):646-57. doi: 10.1111/j.1753-4887.2008.00118.x. Nutr Rev. 2008. Retraction in: Nutr Rev. 2012 Aug;70(8):482. doi: 10.1111/j.1753-4887.2012.00507.x. PMID: 19019027 Free PMC article. Retracted. Review.
-
Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases.Diabetol Metab Syndr. 2014 Jul 28;6(1):80. doi: 10.1186/1758-5996-6-80. eCollection 2014. Diabetol Metab Syndr. 2014. PMID: 25104975 Free PMC article.
-
Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress.Curr Med Chem. 2004 May;11(9):1135-46. doi: 10.2174/0929867043365387. Curr Med Chem. 2004. PMID: 15134511 Review.
-
The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials.Curr Diabetes Rev. 2021;17(9):e011821190404. doi: 10.2174/1573399817666210118145550. Curr Diabetes Rev. 2021. PMID: 33461470 Review.
-
alpha-Lipoic acid as a biological antioxidant.Free Radic Biol Med. 1995 Aug;19(2):227-50. doi: 10.1016/0891-5849(95)00017-r. Free Radic Biol Med. 1995. PMID: 7649494 Review.
Cited by
-
A Study to Evaluate the Effect of Alpha-Lipoic Acid on Neuropathic Symptoms in Diabetic Neuropathy Patients on Gabapentin or Pregabalin.Cureus. 2024 Sep 27;16(9):e70299. doi: 10.7759/cureus.70299. eCollection 2024 Sep. Cureus. 2024. PMID: 39469366 Free PMC article.
-
Alpha Lipoic Acid Modulated High Glucose-Induced Rat Mesangial Cell Dysfunction via mTOR/p70S6K/4E-BP1 Pathway.Int J Endocrinol. 2014;2014:658589. doi: 10.1155/2014/658589. Epub 2014 Oct 30. Int J Endocrinol. 2014. PMID: 25530759 Free PMC article.
-
Targeting the Metabolic Paradigms in Cancer and Diabetes.Biomedicines. 2024 Jan 17;12(1):211. doi: 10.3390/biomedicines12010211. Biomedicines. 2024. PMID: 38255314 Free PMC article. Review.
-
NGF receptors and PI3K/AKT pathway involved in glucose fluctuation-induced damage to neurons and α-lipoic acid treatment.BMC Neurosci. 2020 Sep 17;21(1):38. doi: 10.1186/s12868-020-00588-y. BMC Neurosci. 2020. PMID: 32943002 Free PMC article.
-
Cerium(IV) and Iron(III) Oxides Nanoparticles Based Voltammetric Sensor for the Sensitive and Selective Determination of Lipoic Acid.Sensors (Basel). 2021 Nov 17;21(22):7639. doi: 10.3390/s21227639. Sensors (Basel). 2021. PMID: 34833711 Free PMC article.
References
-
- Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., Vallance P. (2003). Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 23, 1455–145910.1161/01.ATV.0000081742.92006.59 - DOI - PubMed
-
- Ametov A. S., Barinov A., Dyck P. J., Hermann R., Kozlova N., Litchy W. J., Low P. A., Nehrdich D., Novosadova M., O’Brien P. C., Reljanovic M., Samigullin R., Schuette K., Strokov I., Tritschler H. J., Wessel K., Yakhno N., Ziegler D., SYDNEY Trial Study Group (2003). The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 26, 770–77610.2337/diacare.26.3.770 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources